Origenis (Group)

https://www.origenis.com

Origenis GmbH is a privately held German biopharmaceutical company developing brain-penetrating highly selective small molecule medicines and diagnostics for a variety of neurodegenerative and neuroinflammatory diseases. Origenis leverages its unique capabilities in drug design, compound synthesis, and characterization to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis' approach has been validated by multiple partners resulting in a significant IP and R&D portfolio that ensures strong patent protection. *

	Start	2005-11-01 splitoff (MBO)
	Predecessor	Morphochem (Group)
	Industry	drug discovery services
	Person	Almstetter, Michael (Origenis 202012 Managing Director)
	Person 2	Thormann, Michael (Origenis 200609 Managing Director)

	Region	Martinsried
	Country	Germany
	Street	19a Am Klopferspitz
	City	82152 Martinsried
	Tel	+49-89-7801676-0
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2014-11-01)

		* Document for »About Section«: Neuron23 Inc.. (12/16/20). "Press Release: Neuron23 Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group". South San Francisco, CA.

		Record changed: 2023-12-30